



April 20, 2022

Whom it May Concern

Company: KYORIN Holdings, Inc.
Representative: Yutaka Ogihara
Representative Director, President
(Security Code: 4569, TSE Prime)
Contact: Yoshinori Tanifuji
Director, Management Strategy &
Planning Division Corporate Planning
Telephone: 03-3525-4707

NHI Drug Price Listing and Release of a selective P2X3 receptor antagonist for the treatment of chronic cough “Lyfnua[®] Tablet 45 mg”

TOKYO, Japan (April 29, 2022) —Kyorin Pharmaceutical Co., Ltd. (head office: Chiyoda-ku, Tokyo; President and CEO: Shigeru Ogihara; “KYORIN”), a subsidiary of KYORIN Holdings, Inc. (head office: Chiyoda-ku, Tokyo; President and CEO: Yutaka Ogihara), announced that Lyfnua[®] Tablets 45 mg (gefapixant citrate), a selective P2X3 receptor antagonist for the treatment of chronic cough, has been listed on the National Health Insurance (NHI) drug price list today and KYORIN is scheduled to launch it on April 21, 2022.

Lyfnua[®] Tablets was obtained the manufacturing and marketing approval in January 20, 2022 by MSD K.K. (head office: Chiyoda-ku, Tokyo; Representative Director and President: Kyle Tattle; “MSD”). KYORIN will be the sole distributor of Lyfnua[®] Tablets in Japan under an exclusive distribution agreement between KYORIN and MSD’s affiliate company.

Lyfnua[®] Tablets is indicated for refractory chronic cough based on the results from global phase III study and oversea phase III study to evaluated efficacy and safety in patients with refractory or unexplained chronic cough in which cough persist for more than one year.

KYORIN will expand its product portfolio in its strategic respiratory field by exclusively distributing Lyfnua[®] Tablets, aiming to further increase its presence in this area and contribute to the treatment of chronic cough.

The sales forecast of Lyfnua[®] Tablets will be included in the consolidated earnings forecast for 2023 4Q and will be announced at annual financial result on May 11, 2022 (scheduled).

Lyfnua® Tablets 45 mg, selective P2X3 receptor antagonist for the treatment of chronic cough

Trade name	Lyfnua® Tablets 45 mg
Generic name	Gefapixant citrate
Indications	Refractory chronic cough
Dosage and administration	Normally for adults, 45 mg of gefapixant is administered orally twice daily.
NHI price	¥ 203.20
Approved date	January 20,2022
Drug Price Listing date	April 20, 2022
Launch date	April 21, 2022

(Picture)

